|
1
|
European Association for the Study of the
Liver. EASL clinical practice guidelines: Management of chronic
hepatitis B virus infection. J Hepatol. 57:167–185. 2012.PubMed/NCBI
|
|
2
|
World Health Organization. Hepatitis B
Factsheet 204. http://www.who.int/mediacentre/factsheets/fs204/en/index.html.
Accessed 2013
|
|
3
|
Zhou YH, Wu C and Zhuang H: Vaccination
against hepatitis B: the Chinese experience. Chin Med J (Engl).
122:98–102. 2009.
|
|
4
|
Rotman Y, Brown TA and Hoofnagle JH:
Evaluation of the patient with hepatitis B. Hepatology. 49(5
Suppl): S22–S27. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kladney RD, Bulla GA, Guo L, Mason AL, et
al: GP73, a novel Golgi-localized protein upregulated by viral
infection. Gene. 249:53–65. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Riener MO, Stenner F, Liewen H, Soll C, et
al: Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and
its value as a serum marker in hepatocellular carcinomas.
Hepatology. 49:1602–1609. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kladney RD, Cui X, Bulla GA, Brunt EM, et
al: Expression of GP73, a resident Golgi membrane protein, in viral
and nonviral liver disease. Hepatology. 35:1431–1440. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun Y, Yang H, Mao Y, Xu H, et al:
Increased Golgi protein 73 expression in hepatocellular carcinoma
tissue correlates with tumor aggression but not survival. J
Gastroenterol Hepatol. 26:1207–1212. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maitra A and Thuluvath PJ: GP73 and liver
disease: a (Golgi) complex enigma. Am J Gastroenterol.
99:1096–1098. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wright LM, Yong S, Picken MM, Rockey D, et
al: Decreased survival and hepato-renal pathology in mice with
C-terminally truncated GP73 (GOLPH2). Int J Clinical Exp Pathol.
2:34–47. 2009.
|
|
11
|
Iftikhar R, Kladney RD, Havlioglu N,
Schmitt-Graff A, et al: Disease- and cell-specific expression of
GP73 in human liver disease. Am J Gastroenterol. 99:1087–1095.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sterling RK, Jeffers L, Gordon F, Sherman
M, et al: Clinical utility of AFP-L3% measurement in North American
patients with HCV-related cirrhosis. Am J Gastroenterol.
102:2196–2205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen WL, Peng T, Chen XP, et al: Clinical
significance of serum GP73 test in diagnosis of liver diseases.
Chin J Lab Med. 33:333–336. 2010.(In Chinese).
|
|
14
|
Chinese Society of Infectious Diseases and
Parasitology and Chinese Society of Hepatology of Chinese Medical
Association. The programme of prevention and cure for viral
hepatitis. Chin J Hepatol. 8:324–329. 2000.(In Chinese).
|
|
15
|
Pugh RN, Murray-Lyon IM, Dawson JL,
Pietroni MC, et al: Transection of the oesophagus for bleeding
oesophageal varices. Br J Surg. 60:646–649. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sarin SK, Kumar A, Almeida JA, Chawla YK,
et al: Acute-on-chronic liver failure: consensus recommendations of
the Asian Pacific Association for the study of the liver (APASL).
Hepatol Int. 3:269–282. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Scheuer PJ: Classification of chronic
viral hepatitis: a need for reassessment. J Hepatol. 13:372–374.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chinese Society of Hepatology and Chinese
Society of Infectious Diseases, Chinese Medical Association. The
guideline of prevention and treatment for chronic hepatitis B (2010
version). Zhonghua Gan Zang Bing Za Zhi. 19:13–24. 2011.(In
Chinese).
|
|
19
|
Rockey DC, Caldwell SH, Goodman ZD, Nelson
RC, et al: Liver biopsy. Hepatology. 49:1017–1044. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mani H and Kleiner DE: Liver biopsy
findings in chronic hepatitis B. Hepatology. 49(5 Suppl): S61–S71.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bachert C, Fimmel C and Linstedt AD:
Endosomal trafficking and proprotein convertase cleavage of cis
Golgi protein GP73 produces marker for hepatocellular carcinoma.
Traffic. 8:1415–1423. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fimmel CJ and Wright L: Golgi protein 73
as a biomarker of hepatocellular cancer: development of a
quantitative serum assay and expression studies in hepatic and
extrahepatic malignancies. Hepatology. 49:1421–1423. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mao Y, Yang H, Xu H, Lu X, et al: Golgi
protein 73 (GOLPH2) is a valuable serum marker for hepatocellular
carcinoma. Gut. 59:1687–1693. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marrero JA, Romano PR, Nikolaeva O, Steel
L, et al: GP73, a resident Golgi glycoprotein, is a novel serum
marker for hepatocellular carcinoma. J Hepatol. 43:1007–1012. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Norton PA, Comunale MA, Krakover J,
Rodemich L, et al: N-linked glycosylation of the liver cancer
biomarker GP73. J Cellular Biochem. 104:136–149. 2008. View Article : Google Scholar
|
|
26
|
Schwegler EE, Cazares L, Steel LF, Adam
BL, et al: SELDI-TOF MS profiling of serum for detection of the
progression of chronic hepatitis C to hepatocellular carcinoma.
Hepatology. 41:634–642. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi Y, Chen J, Li L, Sun Z, et al: A study
of diagnostic value of golgi protein GP73 and its genetic assay in
primary hepatic carcinoma. Technol Can Res Treat. 10:287–294.
2011.
|
|
28
|
Yamamoto K, Imamura H, Matsuyama Y, Kume
Y, et al: AFP, AFP-L3, DCP, and GP73 as markers for monitoring
treatment response and recurrence and as surrogate markers of
clinicopathological variables of HCC. J Gastroenterol.
45:1272–1282. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qiao Y, Chen J, Li X, Wei H, et al: Serum
gp73 is also a biomarker for diagnosing cirrhosis in population
with chronic HBV infection. Clin Biochem. 47:216–222. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tian L, Wang Y, Xu D, Gui J, et al:
Serological AFP/Golgi protein 73 could be a new diagnostic
parameter of hepatic diseases. International journal of cancer. J
Int Du Cancer. 129:1923–1931. 2011. View Article : Google Scholar
|
|
31
|
Wright LM, Huster D, Lutsenko S, Wrba F,
et al: Hepatocyte GP73 expression in Wilson disease. J Hepatol.
51:557–564. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu X, Wan X, Li Z, Lin C, et al: Golgi
protein 73 (GP73), a useful serum marker in liver diseases. Clin
Chem Lab Med. 49:1311–1316. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cao Q, Mak KM and Lieber CS: Leptin
represses matrix metalloproteinase-1 gene expression in LX2 human
hepatic stellate cells. J Hepatol. 46:124–133. 2007. View Article : Google Scholar
|
|
34
|
Hoofnagle JH: Reactivation of hepatitis B.
Hepatology. 49(5 Suppl): S156–S165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Block TM, Comunale MA, Lowman M, Steel LF,
et al: Use of targeted glycoproteomics to identify serum
glycoproteins that correlate with liver cancer in woodchucks and
humans. Proc Natl Acad Sci USA. 102:779–784. 2005. View Article : Google Scholar : PubMed/NCBI
|
